News & Events

Learn about what's new with CMC Biologics

AGC Biologics Adds Mammalian Production Capacity in Japan

News

New facility will include comprehensive mammalian process development and manufacturing capabilities

BOTHELL, WA and CHIBA, JAPAN; Sept 20, 2018 ─ AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that as part of its ongoing program to expand its production capacities globally, it will establish a new state of the art process development and manufacturing facility at its CDMO facility in Chiba, Japan. The new facility, which is expected to be operational in the second half of 2019, will contain single-use bioreactors at the 500 and 2000L scale and will be ideally suited for the production of monoclonal antibodies (MAbs), fusion proteins and other
types of therapeutic proteins.

AGC Biologics Expands Capacity at Copenhagen, Denmark Facility

News

Strategic expansion will meet increasing global demand for biopharmaceutical development and manufacturing 

COPENHAGEN, Denmark and BOTHELL, Wash., 
Aug. 22, 2018
 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that as part of its global expansion strategy, the company is increasing manufacturing capacity at its Copenhagen, Denmark facility. 

AGC Biologics Inaugurates New Global Headquarters Facility in Bothell, WA

News

Ribbon Cutting Ceremony Held to Commemorate Company Milestone 

BOTHELL, Wash., – July 24, 2018 – AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, celebrated the opening of the company’s new Global Headquarters facility in Bothell, Washington on Wednesday, July 18, 2018.

AGC Biologics to Participate in Boston’s BIO International Convention

News

 

BOTHELL, Wash. – May 30, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company will participate in the upcoming BIO International Convention in Boston, Mass. on June 4-7, 2018.

AGC Biologics Cleared for Commercial Manufacture of Portola's FDA-Approved Andexxa®

News

Drug Substance produced in AGC Biologics' facility in Bothell, Washington 

BOTHELL, Wash. – May 24, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that it will supply bulk drug substance for the launch of Portola Pharmaceuticals' Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

AGC Biologics enters into Commercial Supply Agreement with MacroGenics

News

BOTHELL, Wash. -- May 10, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that in late 2017 it entered into a commercial supply agreement with MacroGenics, a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, for the manufacture of margetuximab, a clinical-stage, novel immune-optimized monoclonal antibody.

AGC Biologics enters into Commercial Manufacturing Agreement with Horizon Pharma plc

News

Manufacture of teprotumumab for treatment of thyroid eye disease
 

COPENHAGEN, DK -- May 3, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today it has entered into an agreement with Horizon Pharma plc for commercial supply of teprotumumab, a monoclonal antibody biologic for the treatment of moderate-to-severe active thyroid eye disease (TED).

Polyvac® Peanut CMO appointed

News

Allergy Therapeutics prepares for manufacturing and clinical development of Polyvac ® Peanut allergy product

- Specialist CMO AGC Biologics engaged -

AGC Biologics Appoints New Site Head/General Manager of Bothell, WA Operations

News

Jin Wang, Ph.D. named Site Head/General Manager

 

BOTHELL, Wash. – April 12, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the appointment of Dr. Jin Wang as Site Head/General Manager of its Bothell, Washington operations. Ms. Wang will provide leadership and site management to ensure AGC Biologics’ continued execution of world class contract development and manufacturing services. Dr. Wang will report to Patricio Massera, Chief Operations Officer.

AGC Biologics Increases Footprint in Bothell, WA

News

Addition of new facilities supports strong company-wide growth initiative

BOTHELL, Wash. –  March 29, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the addition of a new building complex that will house the company’s global headquarters in Bothell, Washington.

Follow Us
Join us on LinkedIn Follow us on Twitter